CN Patent

CN116916927A — 用于用氘化jak抑制剂治疗脱发症的方案

Assigned to Sun Pharmaceutical Industries Ltd · Expires 2023-10-20 · 3y expired

What this patent protects

公开了一种治疗受试者的脱发症的方法，所述脱发症通过施用JAK1和/或JAK2抑制剂来有益治疗。所述方法包括向所述受试者施用有效量的化合物(I)或其药学上可接受的盐。

USPTO Abstract

公开了一种治疗受试者的脱发症的方法，所述脱发症通过施用JAK1和/或JAK2抑制剂来有益治疗。所述方法包括向所述受试者施用有效量的化合物(I)或其药学上可接受的盐。

Drugs covered by this patent

deuruxolitinib-phosphate (DEURUXOLITINIB PHOSPHATE)

Patent Metadata

Patent number: CN116916927A
Jurisdiction: CN
Classification: —
Expires: 2023-10-20
Drug substance claim: No
Drug product claim: No
Assignee: Sun Pharmaceutical Industries Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.